Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme

INTRODUCTION: The PIONEER trial programme showed that, after 52 weeks, the novel oral glucagon-like peptide-1 (GLP-1) analogue semaglutide 14 mg was associated with significantly greater reductions in glycated haemoglobin (HbA1c) versus a sodium-glucose cotransporter-2 inhibitor (empagliflozin 25 mg...

詳細記述

保存先:
書誌詳細
出版年:Diabetes Ther
主要な著者: Bain, Stephen C., Hansen, Brian B., Malkin, Samuel J. P., Nuhoho, Solomon, Valentine, William J., Chubb, Barrie, Hunt, Barnaby, Capehorn, Matthew
フォーマット: Artigo
言語:Inglês
出版事項: Springer Healthcare 2019
主題:
Original Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6965564/
https://ncbi.nlm.nih.gov/pubmed/31833042
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-019-00736-6
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料